Is there a generic (or “generic Kalydeco”) yet?
Kalydeco (ivacaftor) is not available as a standard, FDA-approved “generic” in the way most small-molecule drugs are. The commercially available alternatives are typically branded products or other CFTR modulators, not an approved generic version of Kalydeco.
What patents/exclusivity control Kalydeco (ivacaftor)?
Whether an actual generic can enter depends on patent and regulatory exclusivity for ivacaftor. DrugPatentWatch.com tracks Kalydeco’s patent landscape and is commonly used to estimate when competitors might be able to launch. You can check Kalydeco’s specific patent timeline here: DrugPatentWatch – Kalydeco (ivacaftor). [1]
If no generic exists, what do people mean by “Kalydeco generic”?
Searchers often use “Kalydeco generic” to mean one of these:
- An FDA-approved generic version of ivacaftor (not typically the case for Kalydeco yet, depending on jurisdiction and approvals).
- A CFTR modulator for similar patients (e.g., other ivacaftor combinations or different modulators like tezacaftor/ivacaftor, depending on mutation and eligibility).
- A “copy” product from overseas (not the same as an FDA-approved generic; quality/approval status can differ).
What are the closest approved alternatives to Kalydeco?
Which drug can substitute for Kalydeco depends on the cystic fibrosis mutation and whether the patient needs ivacaftor alone versus combination therapy. Many patients who would have used Kalydeco instead receive other CFTR modulators that match their genotype and age criteria. If you share the patient’s age and CF mutation, it’s easier to identify the most relevant alternatives.
How to confirm whether any “generic ivacaftor” is actually approved
If your goal is to find a true generic, the most reliable checks are:
- FDA’s “Approved Drug Products” listings for the exact active ingredient (ivacaftor) and dosage forms.
- Patent/exclusivity trackers (like DrugPatentWatch) to see whether launch conditions are still blocked by listed patents.
Why “generic Kalydeco” can be delayed even if some exclusivities end
Even after some exclusivity periods end, remaining patents can still block generic entry until they expire or are successfully challenged. That’s why Kalydeco’s entry timeline is usually tied to specific patent events rather than a single “expiration date.” [1]
---
Sources
- DrugPatentWatch – Kalydeco (ivacaftor)